The Zilver PTX stent provides physicians treating peripheral arterial disease in the SFA the combination of mechanical support via stenting with the drug paclitaxel to reduce the risk of restenosis within the vessel.

Cook Medical peripheral intervention division vice president and leader Rob Lyles said, "Many physicians now are convinced drug elution is the future of treating lesions in the leg arteries, and our Australian Zilver PTX launch is an important step in Cook’s efforts to bring this advanced treatment to patients and physicians around the world."

The Zilver PTX stent received CE mark in August 2009 and is now available in Japan, Brazil and other international markets.

The Zilver stent is under the US Food and Drug Administration review and is not available for sale in the US.